Advancing Human-Relevant Systems to Reduce Reliance on Animal Models
Integrated • Predictive • Translational
Accelerating Smarter, More Human-Relevant Medicine
Redefining Preclinical Science Through Human-Relevant Systems
Inspired by Nature.
Empowered by Technology.
Committed to Life.
NAMina Bio is a human-relevant translational intelligence platform.
We integrate 3D bioprinting, organoids, microphysiological systems, and AI-powered analytics to build predictive human disease platforms across the preclinical development lifecycle.
​
We accelerate translational decision-making, reduce reliance on low-predictive animal models, and de-risk early-stage therapeutic development.
​
Aligned with the FDA Modernization Act 2.0 and NIH New Approach Methodologies (NAMs), our mission is to support the transition toward more ethical, data-driven, and clinically relevant preclinical systems.
Our Operating Model
NAMina Bio operates through a phased activation strategy:
Phase 1
Ecosystem Integration & Strategic Channel Partnerships
We align advanced NAM technologies, AI analytics, and organ-on-chip systems with translational oncology programs across the Northeast ecosystem.
​Phase 2
Dedicated Wet-Lab Activation & CRO Execution
The activation of NAMina’s laboratory platform will enable integrated execution of 3D tumour models, organoid validation, and multi-platform translational studies under a unified NAM framework.
Strategic Ecosystem & Collaborative Network
NAMina Bio operates as a translational integration hub, aligning advanced NAM technologies, biotech innovators, and academic institutions within structured preclinical programs.
Through phased activation and curated partnerships, we embed our platforms into high-value scientific environments, accelerating predictive and ethical drug development.
Collaborate in Advancing Human-Relevant Drug Discovery
Biotech & Pharma
NAMina Bio supports biotech and pharmaceutical partners with structured, human-relevant preclinical programs aligned with New Approach Methodologies (NAMs).
​
We integrate 3D systems, microphysiological platforms, and AI-assisted analytics to strengthen translational decision-making and reduce development risk.
Technology Partners
We collaborate with platform innovators in 3D culture, organ-on-chip, synthetic matrices, and AI analytics to embed emerging technologies within structured translational research programs.
​
NAMina provides scientific integration, pilot validation, and ecosystem positioning within high-density biotech environments.
Academic Collaborators
NAMina Bio partners with universities and research institutes to translate discovery science into human-relevant preclinical applications.
​
We support joint grants, co-developed disease models, and translational research initiatives aligned with NAM frameworks.
Our Technology Partners
Collaborating with global innovators to advance predictive, human-relevant preclinical systems.
NAMina Bio works with leading providers in 3D bioprinting, synthetic matrices, organ-on-chip platforms, sequencing, and AI-driven analytics to structure integrated translational programs across disease areas.
Together, we enable more predictive preclinical workflows that reduce reliance on low-translational animal models while strengthening human-relevant data generation.
Explore Our Technology Network →
Research & Innovation Focus
Next-Generation Human-Relevant Models
NAMina Bio develops advanced microphysiological and 3D tumor platforms designed to model complex human disease biology under clinically relevant conditions.
​
Glioma Microphysiological Systems
We are developing dynamic glioma models incorporating oxygen gradients, neurovascular signaling, and therapy response dynamics to support translational oncology research.
PDAC Tumoroid Platforms
Leveraging 3D bioprinting and defined ECM systems, we engineer pancreatic ductal adenocarcinoma models that recapitulate tissue stiffness, adaptive resistance, and microenvironmental conditioning.
AI-Powered Translational Intelligence
We integrate molecular, phenotypic, and clinical datasets within structured computational frameworks to support predictive modeling and biomarker-informed study design.
​
​